DK2171060T3 - Superagonistisk anti-CD28-antistof - Google Patents
Superagonistisk anti-CD28-antistofInfo
- Publication number
- DK2171060T3 DK2171060T3 DK05802650.1T DK05802650T DK2171060T3 DK 2171060 T3 DK2171060 T3 DK 2171060T3 DK 05802650 T DK05802650 T DK 05802650T DK 2171060 T3 DK2171060 T3 DK 2171060T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- superagonist anti
- superagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004055622 | 2004-11-11 | ||
EP05010264 | 2005-05-11 | ||
PCT/EP2005/012050 WO2006050949A2 (de) | 2004-11-11 | 2005-11-10 | Superagonistische anti-cd28 antikörper |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2171060T3 true DK2171060T3 (da) | 2013-12-16 |
Family
ID=36087857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05802650.1T DK2171060T3 (da) | 2004-11-11 | 2005-11-10 | Superagonistisk anti-CD28-antistof |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP2171060B1 (da) |
DK (1) | DK2171060T3 (da) |
ES (1) | ES2437571T3 (da) |
PT (1) | PT2171060E (da) |
WO (1) | WO2006050949A2 (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009112502A1 (en) | 2008-03-13 | 2009-09-17 | Biotest Ag | Agent for treating disease |
BRPI0909048A2 (pt) | 2008-03-13 | 2015-11-24 | Biotest Ag | composição farmacêutica, e, método de tratamento de uma doença autoimune |
HUE028962T2 (en) | 2008-03-13 | 2017-01-30 | Biotest Ag | Active ingredient for treating disease |
US20110082091A1 (en) | 2009-09-28 | 2011-04-07 | Theramab Gmbh | Method for Preclinical Testing of Immunomodulatory Drugs |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
AU2019410073B2 (en) | 2018-12-21 | 2024-08-01 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic CD28 antigen binding molecules |
AR117728A1 (es) | 2018-12-21 | 2021-08-25 | Hoffmann La Roche | Moléculas superagonistas de unión al antígeno cd28 con diana tumoral |
AU2021295549A1 (en) | 2020-06-23 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic CD28 antigen binding molecules targeting Her2 |
EP4172203A1 (en) | 2020-06-25 | 2023-05-03 | F. Hoffmann-La Roche AG | Anti-cd3/anti-cd28 bispecific antigen binding molecules |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
WO2023170474A1 (en) | 2022-03-07 | 2023-09-14 | Novimmune Sa | Cd28 bispecific antibodies for targeted t cell activation |
WO2023193239A1 (en) * | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
US20240254234A1 (en) | 2022-10-21 | 2024-08-01 | Novimmune Sa | PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION |
WO2024094741A1 (en) | 2022-11-03 | 2024-05-10 | F. Hoffmann-La Roche Ag | Combination therapy with anti-cd19/anti-cd28 bispecific antibody |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19722888A1 (de) * | 1997-05-28 | 1998-12-03 | Thomas Prof Dr Huenig | Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten |
DE10160516A1 (de) | 2001-12-04 | 2003-06-12 | Tegenero Gmbh | Peptid oder Protein enthaltend ein C'-D Loop der CD28 Rezeptorfamilie |
WO2003048194A2 (de) * | 2001-12-04 | 2003-06-12 | Tegenero Ag | Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie |
DE10212108A1 (de) | 2002-03-13 | 2003-10-02 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung |
DE10230223A1 (de) | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
DE10352900A1 (de) * | 2003-11-11 | 2005-06-16 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL |
-
2005
- 2005-11-10 WO PCT/EP2005/012050 patent/WO2006050949A2/de active Application Filing
- 2005-11-10 EP EP05802650.1A patent/EP2171060B1/de not_active Not-in-force
- 2005-11-10 EP EP12075032A patent/EP2497829A1/de not_active Withdrawn
- 2005-11-10 ES ES05802650.1T patent/ES2437571T3/es active Active
- 2005-11-10 PT PT58026501T patent/PT2171060E/pt unknown
- 2005-11-10 DK DK05802650.1T patent/DK2171060T3/da active
Also Published As
Publication number | Publication date |
---|---|
EP2497829A1 (de) | 2012-09-12 |
PT2171060E (pt) | 2013-11-18 |
EP2171060B1 (de) | 2013-10-02 |
WO2006050949A3 (de) | 2006-07-13 |
EP2171060A2 (de) | 2010-04-07 |
ES2437571T3 (es) | 2014-01-13 |
WO2006050949A2 (de) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2171060T3 (da) | Superagonistisk anti-CD28-antistof | |
LTPA2018515I1 (lt) | Antagonistiniai IL-17 antikūnai | |
LTC1963368I2 (lt) | Anti-il-17 antikūnai | |
NO20071430L (no) | Anti-OX4OL antistoffer | |
DK1737891T3 (da) | Anti-p-selectin-antistoffer | |
DE602006017373D1 (de) | Madcam-antikörper | |
DK1964852T3 (da) | Anti-ilt7-antistof | |
NO20076607L (no) | TWEAK - bindende antistoff | |
NL1027975A1 (nl) | Antilichamen tegen MAdCAM. | |
DK1599504T3 (da) | Modificeret antistof | |
DK3332808T3 (da) | Humaniserede L243-antistoffer | |
DK1853310T3 (da) | Anti-Abeta-antistofpræparat | |
NO20071069L (no) | Anti-CD154-antistoff | |
DK1771482T3 (da) | HER2-antistofsammensætning | |
ATE414693T1 (de) | Neuartige cis-imidazoline | |
CY2013046I2 (el) | Καινοτομος χρηση των αντισωματων αντι il-1bhta | |
DE502005008168D1 (de) | Pipette | |
BRPI0509495A2 (pt) | anticorpo humanizado | |
DK1812475T3 (da) | Immunglobulinfraktioner | |
FI20041538A0 (fi) | Goniometri | |
DE602005005256D1 (de) | Siebvorrichtung | |
DE502005002052D1 (de) | Transportvorrichtung | |
IS8562A (is) | Ónæmisglóbúlín | |
FI6402U1 (fi) | Julistelista | |
UA10485S (uk) | Павільйон |